Effector Therapeutics
OverviewSuggest Edit
Effector Therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer and other serious diseases.
| Type | Private | |
| Founded | 2012 | |
| HQ | San Diego, CA, US | Map |
| Website | effector.com |
Recent NewsAll News
- eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent
- eFFECTOR’s Zotatifin (eFT226) Downregulates Key Oncogenic Driver Proteins Including RTKs (HER2, FGFR1 and FGFR2) Providing Single Agent Activity and Key Combination Opportunities
- eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors
- eFFECTOR’s Zotatifin Demonstrates in vitro Anti-SARS-CoV-2 Activity in Independent International Study Reported in Peer-Reviewed Journal Nature
Latest Updates
| Employees (est.) (Sept 2021) | 21 | (-4%) |
| Cybersecurity rating | A | More |
Key People/Management at Effector Therapeutics
Larry Lasky
Director
Simeon George
Director
Steve Worland
President and Chief Executive Officer, Director
Premal Patel
Chief Medical Officer
Alana McNulty
Chief Business Officer
Denis Patrick
Director
Effector Therapeutics Office Locations
Effector Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
11180 Roselle St
Effector Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2012 |
Effector Therapeutics total Funding | $101 m |
Effector Therapeutics latest funding size | $16 m |
Time since last funding | 6 years ago |
Effector Therapeutics investors | U.S. Venture Partners (USVP), Osage University Partners, SR One, Novartis Venture Fund, Altitude Life Science Ventures, Astellas Venture Management, Abingworth, The Column Group, Mission Bay Capital, AbbVie Biotech Ventures |
Effector Therapeutics's latest funding round in February 2016 was reported to be $16 m. In total, Effector Therapeutics has raised $101 m
Effector Therapeutics Cybersecurity Score
Effector Therapeutics Online and Social Media Presence
Effector Therapeutics's Trends
Effector Therapeutics Blogs
July 22, 2021
eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent
SAN DIEGO, July 22, 2021 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1b trial evaluating zotatifin (eFT226) as an antiviral agent in an …
October 26, 2020
eFFECTOR’s Zotatifin (eFT226) Downregulates Key Oncogenic Driver Proteins Including RTKs (HER2, FGFR1 and FGFR2) Providing Single Agent Activity and Key Combination Opportunities
SAN DIEGO, OCTOBER 26, 2020 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that data presented over the weekend at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (E…
May 29, 2020
eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors
SAN DIEGO, MAY 29, 2020 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that positive Phase 2 data from its pipeline program tomivosertib (eFT508)
April 29, 2020
eFFECTOR’s Zotatifin Demonstrates in vitro Anti-SARS-CoV-2 Activity in Independent International Study Reported in Peer-Reviewed Journal Nature
SAN DIEGO, April 30, 2020 – eFFECTOR Therapeutics, Inc., today announced that preliminary results from an independent preclinical study showed that oncology product candidate zotatifin (eFT226) had in vitro antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The results of the res…
April 27, 2020
eFFECTOR’s Zotatifin (eFT226) Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Receptor Tyrosine Kinase-Driven Tumor Types in Preclinical Models of Disease
SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced that data presented today in a virtual session at the AACR Annual Meeting,
February 06, 2020
eFFECTOR to Present During BIO CEO & Investor Conference
San Diego, February 6, 2020—eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will present a company overview during the BIO CE…
Effector Therapeutics Frequently Asked Questions
When was Effector Therapeutics founded?
Effector Therapeutics was founded in 2012.
Who are Effector Therapeutics key executives?
Effector Therapeutics's key executives are Larry Lasky, Simeon George and Steve Worland.
How many employees does Effector Therapeutics have?
Effector Therapeutics has 21 employees.
Who are Effector Therapeutics competitors?
Competitors of Effector Therapeutics include aceRNA Technologies, Iproteos and Atrin Pharmaceuticals.
Where is Effector Therapeutics headquarters?
Effector Therapeutics headquarters is located at 11180 Roselle St, San Diego.
Where are Effector Therapeutics offices?
Effector Therapeutics has an office in San Diego.
How many offices does Effector Therapeutics have?
Effector Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies